Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: Randomised double-blind comparison

Lancet

Volumn 354, Issue 9196, 1999, Pages 2106-2111

  Emery, Paul ^a   Zeidler, Henning ^b   Kvien, Tore K ^c   Guslandi, Mario ^d   Naudin, Raphael ^e   Stead, Helen ^f   Verburg, Kenneth M ^g   Isakson, Peter C ^g   Hubbard, Richard C ^g   Geis, G Steven ^g  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c Oslo City Department of Rheumatology   (Norway)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e Searle European Clinical Research and Development   (France)

^f Searle Medical Department   (United Kingdom)

^g PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; DICLOFENAC; PROSTAGLANDIN SYNTHASE INHIBITOR;

ABDOMINAL PAIN; ADULT; AGED; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM INJURY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS;

EID: 0033582115     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)02332-6     Document Type: Article

References (32)

1. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231: 232-35.
2. Needleman P, Turk J, Jakschik BA, Morrison AR, Lefkowith JB. Arachidonic acid metabolism. Ann Rev Biochem 1986; 55: 69-102.
3. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal antiinflammatory drugs: a meta analysis. Ann Intern Med 1 991; 115: 787-96.
4. Singh G, Ramey DR. NSAID induced gastrointestinal complications: the ARAMIS perspective - 1997. J Rheuma toi l 998; 25 (suppl 51): 8-16.
5. Xie W L, Chipmans JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc NatlAcad Sci USA 1991 ; 88: 2692-96.
6. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TIS10, a phorbol ester tumor pro mo t er-indu cible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase-cyclooxygenase homologue. J Biol Chem 1991; 266: 12866-72.
7. Smith WL, DeWitt DL. Protaglandin endoperoxide H synthases-1 and -2.AdvImmunol\996;62: 167-215.
8. Kargman S, Charleson S, Cartwright M, et al. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Am Gastroenerol Assoc 1996; 111: 445-54.
9. Masferrer JL, Zweifel BS, Manning PT, et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Nad Ac ad Sci USA 1994; 91: 3228-32.
10. Seibert K, Zhang Y, Leahy K, et al. Pharamcological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sei USA 1994; 91: 12013-17.
11. Vane JR, Mitchell JA, Appleton I, et al. Inducible isoforms of cyclooxygenase and nitric oxide synthase in inflammation. Proc Natl Acad Sci USA l 994; 91: 2046-50.
12. Sano H, Hla T, Maier JA, et al. In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococal cell wall arthritis. J Clin Invest 1992; 89: 97-108.
13. Crofford LJ, Wilder RL, Ristimaki AP, et al. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues: effects of interleukin-1 , phorbol ester, and corticosteroids. J Clin Invest 1994; 93: 1095-1101.
14. Gierse JK, Hauser SD, Creely DP, et al. Expression and selective inhibition of the constitutive and inducible forms of human cyclooxygenase. Biochem J 1995; 305: 479-84.
15. Laneuville O, Breuer DK, Dewitt DL, Hla T, Funk CD, Smith WL. Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther 1994; 271: 927-34.
16. Simon LS, Lanza FL, Lipsky PE, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 1998; 41: 1591-602.
17. Penning TD, Talley JJ, Bertenshaw SR, et al. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)lH-pyrazol-l-yl]benzenesulfonamide (SC-58635, celecoxity. J Med Chem 1997; 40: 1347-65.
18. Langman MJS, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 1075-78.
19. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Associated 1987 revised criteria for the classificationof rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
20. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. JAMA 1949; 140: 659-62.
21. Cooperating Clinics Committee of American Rheumatism Association. A seven-day variability study of 499 patients with peripheral rheumatoid arthritis. Arthritis Rheum 1965; 8:302-34.
22. Ward JR, Williams HJ, Egger MJ, et al. Comparison of auranofin, gold sodium thiomalate and placebo in the treatment of rheumatoid arthritis. Arthritis Rheum 1983; 26: 1303-15.
23. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35.
24. Kirwan JR, Reeback JS. Stanford health assessment questionnaire modified to assess disability in British patients with rheumatoid arthritis. BrJRheumatol 1986; 25: 206-09.
25. ARA Glossary Committee. Dictionary of the Rheumatic Disease. Vol 1: Signs and symptoms. New York Contact Associates International Ltd, 1988.
26. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 241-49.
27. Kolodny AL. Two double blind trials of diclofenac sodium with aspirin and with naproxen in the treatment of patients with rheumatoid arthritis. J Rheumatol 1988; 15: 1205-11.
28. Barrier CH, Hirschowitz BI. Controversies in the detection and management of nonsteroidal antiinflammatory drug-induced side effects of the upper gastrointestinal tract. Arthritis Rheum 1989; 32: 926-32.
29. Agrawal NM, Van Kerckhove FiEJM, Erhardt LJ, Geis GS. Misoprostol co ad ministe red with diclofenac for prevention of gastroduodenal ulcers: a one-year study. Dig Dis Sci 1995; 40: 1125-31.
30. Roth SH, Bennett RE, Caldron PH, Mitchell CS, Swenson CM. Endoscopie evaluation of the long term effects of diclofenac sodium and naproxen in elderly patients with arthritis. Clin Drug Invest 1995; 9: 171-79.
31. Akdamar K, Ertan A, Agrawal NM, et al. Upper gastrointestinal endoscopy in normal asymptomatic volunteers. Gastrointest Endoscopy 1986; 32: 78-80.
32. Ihmaki T, Varis K, Siurala M. Morphological, functional and immunological state of the gastric mucosa in gastric carcinoma families. Scand J Gastroenterol 1979; 14: 801-12.